Ferroptosis Biology.

GPX4 acute kidney injury ferroptosis iron metabolism lipid peroxidation

Journal

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402

Informations de publication

Date de publication:
29 Apr 2024
Historique:
medline: 30 4 2024
pubmed: 30 4 2024
entrez: 29 4 2024
Statut: aheadofprint

Résumé

Ferroptosis is a regulated cell death modality triggered by iron-dependent lipid peroxidation. Ferroptosis plays a causal role in the pathophysiology of various diseases, making it a promising therapeutic target. Unlike all other cell death modalities dependent on distinct signaling cues, ferroptosis occurs when cellular antioxidative defense mechanisms fail to suppress the oxidative destruction of cellular membranes, eventually leading to cell membrane rupture. Physiologically, only two such surveillance systems are known to efficiently prevent the lipid peroxidation chain reaction by reducing (phospho)lipid hydroperoxides to their corresponding alcohols or by reducing radicals in phospholipid bilayers, thus maintaining the integrity of lipid membranes. Mechanistically, these two systems are linked to the reducing capacity of glutathione peroxidase 4 (GPX4) by consuming glutathione (GSH) on the one and ferroptosis suppressor protein 1 (FSP1, formerly AIFM2) on the other hand. Notably, the importance of ferroptosis suppression in physiological contexts has been linked to a particular vulnerability of renal tissue. In fact, early work has shown that mice genetically lacking Gpx4 rapidly succumb to acute renal failure with pathohistological features of acute tubular necrosis. Promising research attempting to implicate ferroptosis in various renal disease entities, particularly those with proximal tubular involvement, has generated a wealth of knowledge with widespread potential for clinical translation. Here, we provide a brief overview of the involvement of ferroptosis in nephrology. Our goal is to introduce this expanding field for clinically versed nephrologists in the hope of spurring future efforts to prevent ferroptosis in the pathophysiological processes of the kidney.

Identifiants

pubmed: 38684468
pii: 7659824
doi: 10.1093/ndt/gfae097
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.

Auteurs

Tobias Seibt (T)

Institute of Metabolism and Cell Death, Helmholtz Zentrum München, Neuherberg, Germany.
Transplant Center, University Hospital Munich, Ludwig-Maximilians-University (LMU), Munich, Germany.

Adam Wahida (A)

Institute of Metabolism and Cell Death, Helmholtz Zentrum München, Neuherberg, Germany.

Konrad Hoeft (K)

Division of Nephrology and Clinical Immunology, RWTH Aachen University, Aachen, Germany.

Stephan Kemmner (S)

Transplant Center, University Hospital Munich, Ludwig-Maximilians-University (LMU), Munich, Germany.

Andreas Linkermann (A)

Division of Nephrology, Clinic of Internal Medicine 3, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany.
Division of Nephrology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.

Eikan Mishima (E)

Institute of Metabolism and Cell Death, Helmholtz Zentrum München, Neuherberg, Germany.
Division of Nephrology, Rheumatology and Endocrinology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Marcus Conrad (M)

Institute of Metabolism and Cell Death, Helmholtz Zentrum München, Neuherberg, Germany.

Classifications MeSH